AU2015269307C1 - Omega-3 compositions, dosage forms, and methods of use - Google Patents

Omega-3 compositions, dosage forms, and methods of use Download PDF

Info

Publication number
AU2015269307C1
AU2015269307C1 AU2015269307A AU2015269307A AU2015269307C1 AU 2015269307 C1 AU2015269307 C1 AU 2015269307C1 AU 2015269307 A AU2015269307 A AU 2015269307A AU 2015269307 A AU2015269307 A AU 2015269307A AU 2015269307 C1 AU2015269307 C1 AU 2015269307C1
Authority
AU
Australia
Prior art keywords
fatty acids
subject
esterified
dha
epa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015269307A
Other languages
English (en)
Other versions
AU2015269307A1 (en
AU2015269307B2 (en
Inventor
Jorn DYERBERG
Bruce A. Miller
Olav SANDNES
Steen Stender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Ingredients LLC
Original Assignee
Marine Ingredients LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Ingredients LLC filed Critical Marine Ingredients LLC
Publication of AU2015269307A1 publication Critical patent/AU2015269307A1/en
Application granted granted Critical
Publication of AU2015269307B2 publication Critical patent/AU2015269307B2/en
Publication of AU2015269307C1 publication Critical patent/AU2015269307C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2015269307A 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use Active AU2015269307C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462009145P 2014-06-06 2014-06-06
US62/009,145 2014-06-06
US201462019289P 2014-06-30 2014-06-30
US62/019,289 2014-06-30
PCT/US2015/034372 WO2015188046A1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Publications (3)

Publication Number Publication Date
AU2015269307A1 AU2015269307A1 (en) 2017-01-05
AU2015269307B2 AU2015269307B2 (en) 2019-03-14
AU2015269307C1 true AU2015269307C1 (en) 2019-10-03

Family

ID=54767418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015269307A Active AU2015269307C1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Country Status (14)

Country Link
US (4) US9675575B2 (enExample)
EP (2) EP3151826A4 (enExample)
JP (2) JP6755186B2 (enExample)
KR (1) KR102400958B1 (enExample)
CN (1) CN106687113B (enExample)
AU (1) AU2015269307C1 (enExample)
BR (1) BR112016028561A8 (enExample)
CA (1) CA2950344C (enExample)
CL (1) CL2016003131A1 (enExample)
MX (1) MX2016015791A (enExample)
MY (1) MY186566A (enExample)
RU (1) RU2741965C2 (enExample)
TW (1) TWI725937B (enExample)
WO (1) WO2015188046A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
AU2015269307C1 (en) * 2014-06-06 2019-10-03 Marine Ingredients, Llc Omega-3 compositions, dosage forms, and methods of use
CN110958731A (zh) 2018-09-21 2020-04-03 鸿盛国际有限公司 发光二极管并联电路
FR3103355B1 (fr) 2019-11-26 2024-05-31 Polaris Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés
FR3151183A1 (fr) 2023-07-20 2025-01-24 Microphyt Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
US20130225533A1 (en) * 2010-03-10 2013-08-29 Nordic Naturals, Inc. Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
JP2000501131A (ja) * 1995-11-24 2000-02-02 ロダース・クロックラーン・ビー・ブイ 魚油をベースとする組成物
US7799365B2 (en) * 2001-04-06 2010-09-21 Burnbrae Farms Limited Liquid egg composition including fish oil with omega-3 fatty acid
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070020340A1 (en) * 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
CA2625338A1 (en) 2005-10-07 2007-06-14 Ocean Nutrition Canada Ltd. Salts of fatty acids and methods of making and using thereof
EP2364701A1 (en) 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
EP3263101A1 (en) 2005-12-21 2018-01-03 Brudy Technology, S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
WO2007149592A2 (en) 2006-06-23 2007-12-27 The Procter & Gamble Company Concentrated omega-3 fatty acids and mixtures containing them
WO2008036353A2 (en) 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
EP2147088A4 (en) * 2007-04-26 2010-05-05 Patrick Adlercreutz FERTILIZED MILK OILS COMPRISING MULTIPLE-UNSATURATED FATTY ACIDS, COMPRISING EICOSAPENTAIC ACID (EPA) AND DOCOSAHEXAIC ACID (DHA), AND MANUFACTURING METHOD THEREFOR
US20100119600A1 (en) * 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
KR101502191B1 (ko) * 2007-07-30 2015-03-12 닛폰 스이산 가부시키가이샤 Ｅｐａ 농축유 및 ｄｈａ 농축유의 제조 방법
KR101045397B1 (ko) 2008-07-04 2011-06-30 주식회사동우산업 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
EP2323647B1 (en) * 2008-08-07 2014-09-10 SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. Long-term treatment of symptomatic heart failure
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
US9532963B2 (en) * 2009-03-09 2017-01-03 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
CN101695487B (zh) * 2009-09-22 2012-01-18 北京百慧生化制药有限责任公司 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
US9675572B2 (en) 2010-04-23 2017-06-13 The United States Of America As Represented By The Secretary Of The Army Intravenous omega-3 fatty acid compositions and method of use
CN103221524B (zh) * 2010-09-24 2021-01-01 普罗诺瓦生物医药挪威公司 用于浓缩omega-3脂肪酸的方法
WO2013086323A2 (en) * 2011-12-08 2013-06-13 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
EP2793867B1 (en) * 2011-12-22 2021-01-20 Baes, Erik Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
JP6370775B2 (ja) 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
WO2014057362A2 (en) 2012-09-24 2014-04-17 Aker Biopharma As Omega -3 compositions
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
AU2015269307C1 (en) * 2014-06-06 2019-10-03 Marine Ingredients, Llc Omega-3 compositions, dosage forms, and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225533A1 (en) * 2010-03-10 2013-08-29 Nordic Naturals, Inc. Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAMS, H. et al., "Omega-3 fatty acids and cardiovascular disease: new developments and applications", Postgraduate Medicine, vol. 125, no. 6, 31 October 2013, pages 100-113 *

Also Published As

Publication number Publication date
EP3151826A4 (en) 2018-01-24
RU2016149416A (ru) 2018-07-10
US20210308086A1 (en) 2021-10-07
KR20170018825A (ko) 2017-02-20
TWI725937B (zh) 2021-05-01
US20180303784A1 (en) 2018-10-25
EP3906920A1 (en) 2021-11-10
US10172819B2 (en) 2019-01-08
US11160777B2 (en) 2021-11-02
RU2016149416A3 (enExample) 2018-12-05
JP6755186B2 (ja) 2020-09-16
CN106687113A (zh) 2017-05-17
TW201613571A (en) 2016-04-16
US20170252313A1 (en) 2017-09-07
JP2020105224A (ja) 2020-07-09
KR102400958B1 (ko) 2022-05-20
CA2950344C (en) 2023-09-19
RU2741965C2 (ru) 2021-02-01
BR112016028561A2 (pt) 2017-08-22
US9675575B2 (en) 2017-06-13
CL2016003131A1 (es) 2017-06-09
AU2015269307A1 (en) 2017-01-05
BR112016028561A8 (pt) 2021-06-29
US20160243068A1 (en) 2016-08-25
CN106687113B (zh) 2021-09-03
MY186566A (en) 2021-07-27
JP2017516811A (ja) 2017-06-22
MX2016015791A (es) 2017-05-30
CA2950344A1 (en) 2015-12-10
EP3151826A1 (en) 2017-04-12
US10034849B2 (en) 2018-07-31
AU2015269307B2 (en) 2019-03-14
WO2015188046A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
US11160777B2 (en) Omega-3 compositions, dosage forms, and methods of use
JP6953504B2 (ja) エイコサペンタエン酸アルキルエステルを含有する組成物及びその製造方法
CN104187627B (zh) 一种降血脂组合物及其在制备具有降血脂功能的保健食品中的应用
LU87570A1 (fr) Composition d'acides gras
US20100048705A1 (en) Methods of treating and preventing neovascularization with omega-3 polyunsaturated fatty acids
CN108096237A (zh) 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
JP2001247473A (ja) インスリン抵抗性改善剤
JP2017532381A (ja) 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用
CN106459833A (zh) 源自水产物的游离一元不饱和脂肪酸或其低级醇酯的制造方法
JP4707839B2 (ja) 糖尿病予防治療剤
JP4904751B2 (ja) 生体内ｄｈａ合成促進剤
CN104523590B (zh) 一种丁酸氯维地平脂肪乳注射液
JP3550176B2 (ja) トコフェロール強化精製エゴマ油、それを含有する脂肪輸液剤及び経口投与製剤
KR20190118556A (ko) 악액질의 예방 및/또는 치료용 오메가-3 지방산 조성물
RU2571503C1 (ru) Фармацевтическая композиция, обладающая свойствами активировать витамин д рецепторы
JP2021084895A (ja) ω３脂肪酸の自己乳化製剤
JPH08198749A (ja) 糖尿病患者用脂肪輸液剤
Poudel-Tandukar et al. ROLE OF EICOSAPENTAENOIC ACID IN MENTAL HEALTH
WO2015185240A1 (en) Compositions containing simvastatin in omega-3 polyunsaturated fatty acids

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JUN 2019

TH Corrigenda

Free format text: IN VOL 33 , NO 25 , PAGE(S) 3584 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME MARINE INGREDIENTS, LLC, APPLICATION NO. 2015269307 CORRECT THE DATE OF THE STATEMENTS FILED TO READ 6 JUNE 2019 AND 14 JUNE 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENTS FILED 06 JUN 2019 AND 14 JUN 2019

FGA Letters patent sealed or granted (standard patent)